Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. ACN
9. NVO
10. COHR

Go back to Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
ENANTA PHARM (NASDAQ: ENTA) Delayed: 12.11 -0.09 (0.74%)
Previous Close $12.20    52 Week High $34.49 
Open $12.28    52 Week Low $20.39 
Day High $12.28    P/E N/A 
Day Low $11.94    EPS $-3.18 
Volume 217,216